$34.73
1.98% yesterday
Nasdaq, Nov 20, 10:00 pm CET
ISIN
US89422G1076
Symbol
TVTX

Travere Therapeutics Inc Stock price

$34.73
+6.84 24.52% 1M
+17.17 97.78% 6M
+17.31 99.37% YTD
+16.87 94.46% 1Y
+14.81 74.35% 3Y
+9.86 39.65% 5Y
+15.30 78.74% 10Y
+34.55 19,194.44% 20Y
Nasdaq, Closing price Thu, Nov 20 2025
-0.70 1.98%
ISIN
US89422G1076
Symbol
TVTX
Industry

Key metrics

Basic
Market capitalization
$3.1b
Enterprise Value
$3.2b
Net debt
$56.8m
Cash
$254.5m
Shares outstanding
89.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.1 | 6.4
EV/Sales
7.3 | 6.5
EV/FCF
negative
P/B
42.2
Financial Health
Equity Ratio
9.9%
Return on Equity
-544.3%
ROCE
-22.2%
ROIC
-36.8%
Debt/Equity
4.2
Financials (TTM | estimate)
Revenue
$435.8m | $486.6m
EBITDA
$-36.6m | $-66.0m
EBIT
$-89.7m | $-101.0m
Net Income
$-88.5m | $-83.5m
Free Cash Flow
$-107.5m
Growth (TTM | estimate)
Revenue
114.2% | 108.7%
EBITDA
84.8% | 69.2%
EBIT
67.9% | 60.6%
Net Income
74.8% | 74.1%
Free Cash Flow
70.9%
Margin (TTM | estimate)
Gross
97.6%
EBITDA
-8.4% | -13.6%
EBIT
-20.6%
Net
-20.3% | -17.2%
Free Cash Flow
-24.7%
More
EPS
$-0.9
FCF per Share
$-1.2
Short interest
12.2%
Employees
385
Rev per Employee
$610.0k
Show more

Is Travere Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Travere Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Travere Therapeutics Inc forecast:

18x Buy
86%
3x Hold
14%

Analyst Opinions

21 Analysts have issued a Travere Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Travere Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
436 436
114% 114%
100%
- Direct Costs 10 10
6% 6%
2%
425 425
120% 120%
98%
- Selling and Administrative Expenses 252 252
15% 15%
58%
- Research and Development Expense 210 210
2% 2%
48%
-37 -37
85% 85%
-8%
- Depreciation and Amortization 53 53
36% 36%
12%
EBIT (Operating Income) EBIT -90 -90
68% 68%
-21%
Net Profit -89 -89
75% 75%
-20%

In millions USD.

Don't miss a Thing! We will send you all news about Travere Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Travere Therapeutics Inc Stock News

Neutral
The Motley Fool
3 days ago
New York City-based Armistice Capital sold 2,152,000 shares of Travere Therapeutics for an estimated $29.3 million in the third quarter. At quarter-end, the fund reporting holding 6.7 million shares of Travere Therapeutics valued at $160.7 million.
Neutral
Business Wire
10 days ago
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on November 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 25,700 shares of its common stock. These inducement RSUs are subject to the terms of Traver...
Neutral
Business Wire
15 days ago
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced new data from the Phase 3 DUPLEX Study demonstrating that patients with focal segmental glomerulosclerosis (FSGS) treated with FILSPARI® (sparsentan) were significantly more likely to reach proteinuria levels below 0.7 g/g compared to those receiving the maximum labeled dose of irbesartan, and achie...
More Travere Therapeutics Inc News

Company Profile

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Head office United States
CEO Eric Dube
Employees 385
Founded 2008
Website travere.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today